RevenanasBook a free audit

Funding

Norwegian biotech startup Vitroscope secures $7M to scale living human tissue technology

November 3, 2026

Biotech

Funding

Key Facts

Signal Type

Funding

Industry

Biotech

Companies

Vitroscope, Cerberus Ventures, YZR Capital

Date

November 3, 2026

What Happened

Vitroscope, a Trondheim-based biotech startup, raised $7 million in a financing package, comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital, alongside $2 million in additional funding. The company is developing technology for studying living human tissue.

Who Is Affected

Vitroscope's operations will expand as it scales its platform. The funding also signals investor confidence in Nordic biotech innovation, affecting competitive dynamics in the region.

Market Impact

  • Post-raise companies typically increase spending on lab informatics, data management, and scaling infrastructure.
  • Norwegian biotech ecosystem gains momentum, attracting more VC attention.
  • Sales reps targeting biotech startups now have a clear entry point with a newly funded, scaling company.

What to Watch

Watch for Vitroscope's hiring and technology adoption in the coming quarters. Also monitor follow-on funding and potential enterprise partnerships that could open doors for vendors.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner